A biotech developing botulinum toxin therapies (ABP-450) for migraine, cervical dystonia, and gastroparesis — think Botox for medical conditions, not wrinkles.
No revenue reported; the company burns cash, with net losses of USD 0.38B in 2023 and USD 0.04B in 2025, though 2024 showed a one-off USD 0.04B gain.
No approved products or sales, so any moat is hypothetical. Competitors like AbbVie (Botox) and Ipsen (Dysport) already dominate botulinum toxin markets with established brands and regulatory approvals.
Key events, in time order
None yet
None yet
AEON was added to OKX's X Drops, indicating a new listing and potential trading activity. The discussion focuses on exchange listings and associated events.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
